An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
Status:
Unknown status
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
If autism is the consequence of a chronic inflammatory process preventing the infant brain
from forming the proper neural connections, then treatment that reduces inflammation might
have a positive impact on autism. IGIV treatment has been known to suppress inflammation and
has been used in the treatment of inflammatory conditions and autoimmune diseases.